Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of October 2025. The report details a specific transaction in the company's own shares executed on October 30, 2025, pursuant to an existing share buyback programme. The transaction was conducted through BNP Paribas SA under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on share repurchase activity and does not provide revenue, profit, cash flow, or debt metrics.
- Shares Purchased (Oct 30): 180,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,726.50p; highest price paid was 1,780.00p.
- Volume-Weighted Average Price (VWAP): 1,756.23p.
- Trading Venues: Purchases were executed on XLON (London Stock Exchange), CHIX, and BATE.
- Treasury Holdings: Following this purchase, GSK holds 254,593,344 ordinary shares in treasury.
- Shares in Issue: 4,060,827,442 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 6.27% of total voting rights.
Material Changes vs. Prior Period
The filing does not provide comparative financial performance data (e.g., revenue or earnings) against prior periods. However, it notes that since the commencement of the current buyback agreement on September 30, 2025, the Company has purchased an aggregate of 7,128,500 ordinary shares.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, management commentary on operational outlook, or specific risk factors beyond a standard cautionary statement. GSK notes that forward-looking statements are subject to risks and uncertainties described in its 2024 Annual Report on Form 20-F and its Q3 2025 Results. The purchased shares are to be held as Treasury shares.
Investor Verification Checklist
- Verify the total cost of the October 30 transaction (180,000 shares at a VWAP of 1,756.23p).
- Confirm the remaining capacity under the non-discretionary buyback agreement announced on September 30, 2025.
- Review the impact of the 6.27% treasury holding on diluted earnings per share calculations.
- Check the Q3 2025 Results referenced in the cautionary statement for broader financial context not included in this filing.